background
passiv
immunotherapi
use
polyclon
antibodi
immunoglobulin
use
centuri
treatment
postexposur
prophylaxi
variou
infect
toxin
heterolog
polyclon
antibodi
obtain
anim
hyperimmunis
pathogen
toxin
aim
aim
review
examin
histori
anim
polyclon
antibodi
therapi
use
develop
safe
effect
product
potenti
applic
human
emerg
neglect
infecti
diseas
method
literatur
search
ovid
medlin
ovid
embas
databas
undertaken
identifi
articl
safeti
efficaci
ongo
develop
polyclon
antibodi
search
contain
databasespecif
mesh
emtre
term
combin
pertin
textword
polyclon
antibodi
rareneglect
aim
review
examin
histori
anim
polyclon
antibodi
therapi
use
develop
safe
effect
product
potenti
futur
applic
human
emerg
virus
neglect
tropic
diseas
literatur
search
undertaken
experienc
medic
librarian
identifi
articl
safeti
polyclon
von
behr
kitasato
discov
sera
rabbit
immunis
diphtheria
tetanu
abl
protect
expos
mice
anim
deriv
antidiphtheria
serum
use
human
european
epidem
concurr
phisalex
bertrand
demonstr
blood
hors
immunis
viper
aspi
european
viper
antivenin
properti
sera
human
anim
subsequ
use
manag
ill
caus
virus
measl
varicella
pandem
spanish
influenza
antirabi
polyclon
antibodi
prepar
hyperimmunis
hors
develop
earli
centuri
preantibiot
era
serum
therapi
also
appli
bacteri
infect
pneumococc
pneumonia
meningococc
mening
streptococc
scarlet
fever
earli
crude
prepar
serum
often
contamin
anim
protein
result
serum
sick
anaphylaxi
limit
safe
applic
antibiot
bacteri
infect
larg
supersed
serum
therapi
late
howev
improv
enzymat
digest
purif
equin
immunoglobulin
enabl
safer
polyclon
antibodi
therapi
develop
envenom
rabi
exposur
viral
infect
hepat
b
varicellazost
viru
respiratori
syncyti
viru
rsv
develop
monoclon
antibodi
mab
enabl
larg
quantiti
specif
antibodi
produc
humanis
mab
allow
use
treatment
chronic
diseas
repeat
administr
howev
polyclon
antibodi
still
prove
effect
monoclon
antibodi
treatment
mani
infecti
diseas
date
monoclon
antibodi
therapi
produc
either
autoimmun
condit
system
lupu
erythematosu
crohn
diseas
neoplast
condit
licenc
monoclon
antibodi
infecti
target
palivizumab
rsv
contrast
monoclon
antibodi
polyclon
therapi
target
multipl
epitop
protect
epitop
mutat
addit
may
need
low
avid
monoclon
antibodi
prepar
compar
polyclon
prepar
neutralis
given
amount
toxin
pathogen
gener
case
antitoxin
snake
envenom
anim
deriv
polyclon
antibodi
therapi
success
safe
appli
medic
overdos
colchicin
digoxin
ii
poison
snake
arachnid
marin
plant
toxin
iii
postexposur
prophylaxi
rabi
viru
polyclon
antibodi
product
made
larg
quantiti
costeffect
respond
great
endem
demand
asia
africa
well
potenti
pandem
situat
global
advers
reaction
human
animalderiv
polyclon
antibodi
usual
due
presenc
highli
immunogen
anim
protein
type
hypersensit
reaction
includ
anaphylaxi
begin
within
minut
type
hypersensit
serumsick
result
deposit
immun
complex
small
vessel
skin
joint
kidney
develop
point
three
week
take
clear
inject
antibodi
antibodi
consist
antigen
bind
fab
fraction
link
disulphid
bond
f
ab
crystallis
fraction
fc
reactogen
fc
fragment
induc
complementmedi
urticaria
angioedema
lymphadenopathi
arthralgia
nephropathi
fc
remov
retent
immunogen
f
ab
f
ab
compon
first
appli
digoxin
antiserum
f
ab
f
ab
fragment
isol
initi
salt
precipit
subsequ
sinc
via
chromatograph
purif
complement
mediat
anyphylactoid
reaction
fever
hypersensit
reduc
care
elimin
final
product
bacteri
endotoxin
pyrogen
well
protein
cell
aggreg
pasteuris
ultrafiltr
addit
chromatographi
combin
puriti
safeti
advanc
seriou
advers
event
rare
even
rare
equin
rabi
immunoglobulin
erig
anaphylact
shock
report
less
treatment
serum
sick
allgrad
advers
event
ammonium
sulphat
precipit
f
ab
main
method
purif
chromatographi
introduc
exampl
current
product
techniqu
rabi
equin
immunoglobulin
produc
qmsi
queen
saovabha
memori
institut
bangkok
favirab
sanofipasteur
well
equin
snake
antivenin
briefli
techniqu
involv
hyperimmunis
sourc
anim
daili
sever
day
collect
sera
week
last
inject
enabl
antibodi
affin
matur
result
highli
avid
concentr
product
reduc
coadminist
load
contamin
anim
protein
purif
process
often
start
anionexchang
chromatographi
step
isol
immunogen
hors
igg
subclass
remov
immunoglobulin
protein
cell
aggreg
contamin
enzymat
cleavag
digest
low
ph
pepsin
igg
fc
activ
f
ab
f
ab
region
reduc
advers
reaction
second
anionexchang
chromatographi
exclud
fc
fragment
protein
cell
aggreg
result
low
ph
pepsin
digest
well
bacteri
pyrogen
european
guidelin
requir
anim
immunosera
testneg
pyrogen
final
pasteuris
step
involv
heattreat
h
c
destroy
virus
thermocoagul
excess
protein
high
perform
liquid
chromatographi
use
control
puriti
final
product
usual
content
coval
f
ab
f
ab
fragment
polymersaggreg
importantli
immunoreact
remain
intact
step
final
antivir
antibodi
titr
determin
exampl
elisa
seroneutralis
assay
antivir
immunoglobulin
variat
product
process
includ
applic
potassium
sulphat
f
ab
fc
separ
precipit
nonimmunoglobulin
protein
capryl
acid
precipit
purifi
whole
igg
result
near
total
exclus
albumin
less
activ
complement
well
lower
total
proteinprotein
aggreg
compar
ammonium
sulphat
precipit
centrifug
elimin
cellular
element
protein
preserv
ad
final
product
prevent
bacteri
fungal
contamin
refriger
avoid
prolong
storag
avoid
proteincel
reaggreg
precipit
apart
pasteuris
step
neutralis
pathogen
includ
lowph
pepsin
hydrolysi
hightemperatur
capryl
acid
precipit
lipolys
envelop
virus
herp
sindbi
west
nile
virus
ultranano
filtrat
eg
use
gaug
filter
viru
bacteri
remov
subcultur
confirm
bacteri
steril
recognit
inconsist
antivenin
product
qualiti
releas
guidelin
product
control
regul
snake
antivenom
larg
rel
molecular
mass
mr
bival
antibodi
igg
f
ab
fragment
smaller
volum
distribut
longer
halflif
human
bodi
lower
mr
f
ab
fragment
igg
f
ab
fragment
elimin
occur
mainli
format
elimin
immun
complex
catabol
wherea
f
ab
clear
renal
longer
halflif
mean
antivenin
made
igg
f
ab
persist
reduc
rebound
symptom
envenom
associ
f
ab
antitoxin
addit
preserv
larg
mr
antivenin
vascular
compart
draw
venin
tissu
bloodstream
form
antiveninvenom
complex
promot
venom
clearanc
howev
recent
human
pharmacokinet
data
suggest
f
ab
also
extravas
tissu
tissu
penetr
may
assist
neutral
virus
infect
variou
organ
cleav
fc
fragment
whilst
reduc
advers
event
possibl
reduc
potenti
effect
gener
natur
immun
toward
pathogen
toxin
fc
interact
antigenpres
may
stimul
promot
develop
activ
immun
toward
exposur
featur
may
implic
select
molecul
type
product
polyclon
immunotherapi
particularli
postexposur
prophylaxi
virus
merscov
ebola
dose
interv
longer
therefor
dose
regimen
pragmat
igg
f
ab
igg
also
may
promot
develop
host
immun
howev
need
balanc
increas
risk
hypersensit
reaction
fc
molecul
halftim
elimin
product
plasma
compart
analyz
intraven
iv
administr
f
ab
avian
influenza
healthi
volunt
receiv
dose
healthi
volunt
receiv
dose
plasmat
elimin
f
ab
one
iv
infus
mean
h
infus
h
apart
mean
h
result
indic
persist
equin
f
ab
plasma
durat
therapeut
protocol
evid
slight
accumul
day
day
fifth
infus
equin
f
ab
remain
detect
elisa
plasma
gml
day
result
consist
anoth
human
studi
intraven
equin
f
ab
plasma
h
later
catabol
f
ab
around
day
thu
protect
induc
may
continu
sever
day
end
treatment
protocol
patient
immun
gener
host
antibodi
metaanalysi
seven
studi
cochran
review
conclud
adrenalin
premed
agent
significantli
reduc
earli
advers
reaction
addit
earli
use
adrenalin
anaphylact
reaction
post
antivenin
effect
ovin
sheepderiv
product
may
somewhat
less
reactogen
equin
product
latter
econom
produc
given
larger
amount
sera
avail
longer
halflif
reduc
requir
readministr
equin
antivenin
may
also
superior
antitoxin
effect
compar
ovin
record
case
viral
prion
transmiss
equinederiv
antitoxin
current
process
aim
preserv
safeti
record
initi
measur
eg
donor
select
epidemiolog
exclus
quarantin
health
statu
anim
process
final
product
reduc
risk
contamin
viru
anim
contain
within
close
flock
maintain
area
free
insect
vector
certain
arbovirus
exampl
rattlesnak
viper
digoxin
antitoxin
manufactur
south
australia
region
free
prion
mani
viral
pathogen
sourc
anim
may
also
vaccin
local
pathogen
rabi
anthrax
viral
equin
encephalitid
molecular
diagnost
screen
anim
virus
may
perform
recordkeep
regular
stock
inspect
contribut
qualiti
control
rigor
applic
process
vari
resourc
avail
eg
resourcechalleng
countri
much
world
antiveninantitoxin
requir
produc
safeti
measur
may
employ
polyval
sourc
anim
immunis
one
venin
polyclon
antivenin
higher
rate
advers
reaction
monoval
sourc
anim
immunis
one
venin
polyclon
antivenin
eg
vs
australian
produc
csl
snake
antivenin
due
part
larger
volum
requir
administ
treatment
polyval
rather
monoval
polyclon
antibodi
clinic
studi
demonstr
safeti
efficaci
equin
immunoglobulin
therapi
even
given
pregnant
women
passag
f
ab
across
placenta
expect
thu
teratogen
anticip
filipino
recipi
f
ab
equin
rabi
immunoglobulin
erig
favirab
sanofi
pasteur
lyon
franc
two
develop
rabi
neither
receiv
postexposur
prophylaxi
pep
strictli
per
guidelin
subject
cohort
sustain
bite
laboratoryconfirm
rabid
anim
report
case
rabi
person
bitten
rabid
dog
philippin
singl
record
pep
failur
due
locat
bite
lip
local
erig
infiltr
difficult
offici
protocol
receiv
mix
intraderm
intramuscular
rabi
vaccin
result
emphasis
import
adher
rabi
guidelin
administ
pep
safeti
current
erig
product
also
demonstr
clinic
trial
post
market
surveil
erig
recipi
philippin
thailand
india
recipi
develop
local
reaction
system
reaction
reaction
may
due
coadminist
tetanu
toxoid
retrospect
review
patient
thailand
receiv
either
human
rabi
immunoglobulin
hrig
erig
demonstr
erig
recipi
advers
event
versu
hrig
recipi
howev
broad
date
rang
includ
erig
produc
introduct
modern
purif
techniqu
serum
sick
report
erig
recipi
vs
hrig
recipi
death
report
antivenin
also
effect
randomis
prospect
control
human
studi
mice
studi
retrospect
human
studi
human
case
report
provid
evid
effect
safe
treatment
lifethreaten
envenom
coagulopathi
sever
human
report
confirm
efficaci
variou
snake
antivenin
tabl
efficaci
rattlesnak
antivenin
studi
particularli
usa
rattlesnak
predomin
introduct
rattlesnak
whole
igg
polyval
crotalid
antivenin
acp
reduc
mortal
deliv
health
care
facil
unit
state
retrospect
chart
review
reveal
fraction
crotalida
polyval
immun
f
ab
crofab
effect
avoid
fasciotomi
whole
igg
product
acp
year
review
crofab
reveal
respons
rate
amongst
case
sever
envenom
includ
neurotox
whilst
anoth
seri
sever
envenom
respond
crofab
literatur
review
control
observ
studi
confirm
efficaci
safeti
crofab
crofab
also
demonstr
effect
paediatr
patient
howev
south
american
studi
demonstr
local
produc
whole
igg
antivenin
effect
two
f
ab
prepar
anaphylactoid
reaction
amongst
fraction
product
comparison
f
ab
f
ab
rattlesnak
antivenin
demonstr
signific
reduct
late
coagulopathi
receiv
f
ab
compar
f
ab
vs
due
longer
halflif
dival
monoval
product
advantag
f
ab
f
ab
demonstr
antivenin
epidemiolog
data
europ
demonstr
introduct
antivenin
result
severalfold
decreas
snakebit
mortal
australian
snake
antivenin
consid
effect
neutralis
neurotox
effect
procoagul
effect
plasma
transfus
recommend
along
antivenin
limit
current
australian
antivenin
disput
howev
safeti
snake
antivenin
improv
antibodi
fraction
modern
process
whole
igg
rattlesnak
antivenin
eg
antivenin
crotalida
polyval
acp
associ
frequenc
immedi
delay
reaction
halv
remov
fc
implant
modern
purif
method
eg
crofab
metaanalysi
crofab
reveal
immedi
hypersensit
rate
serum
sick
even
lower
rate
report
subsequ
studi
case
immedi
hypersensit
reaction
serum
sick
likewis
advers
event
rate
bothrop
antivenin
improv
ammonium
sulphat
precipit
whole
igg
prepar
capryl
acid
precipit
whole
igg
f
ab
antivenin
metaanalysi
conduct
us
author
observ
control
studi
variou
snake
antivenin
exclud
rattlesnak
antivenin
metaanalysi
report
tabl
simpl
linear
weight
sampl
size
studi
appli
weight
mean
standard
deviat
set
studi
compar
use
formula
isol
effect
independ
variabl
antivenin
given
otherwis
similar
popul
distribut
determin
estim
percentag
differ
z
give
confid
interv
report
analysi
demonstr
f
ab
f
ab
safer
whole
igg
reduct
advers
event
introduct
purif
techniqu
except
reduct
anaphylaxi
pre
post
type
antivenin
combin
approxim
million
scorpion
envenom
annual
result
death
autonom
overstimul
andor
overwhelm
inflammatori
respons
randomis
control
trial
rct
antiscorpion
f
ab
arizona
reveal
signific
differ
follow
rapid
symptom
resolut
midazolam
requir
plasma
venom
level
compar
placebo
metaanalysi
rct
observ
studi
demonstr
effect
new
world
american
scorpion
envenom
old
world
advers
event
higher
nonrandomis
trial
eg
serum
sick
occur
treat
one
studi
last
day
antivenin
highli
effect
reduc
symptom
durat
h
min
advers
event
infrequ
rct
howev
metaanalysi
includ
indian
old
world
control
trial
scorpion
f
ab
antivenin
revers
clinic
envenom
effect
antivenin
three
oldworld
studi
includ
metaanalysi
demonstr
efficaci
uncontrol
indian
studi
scorpion
f
ab
antivenin
respond
one
mild
reaction
prospect
casecontrol
seri
india
patient
age
year
demonstr
dopamin
dobutamin
requir
reduc
recoveri
faster
receiv
scorpion
antivenin
control
trial
saudi
arabia
report
reduct
mortal
mild
reaction
review
studi
indian
uncontrol
trial
scorpion
f
ab
antivenin
reveal
efficaci
oppos
whole
igg
trial
howev
withdraw
igg
scorpion
antisera
usa
altern
substitut
result
increas
icu
admiss
sting
saudi
arabian
data
demonstr
reduct
death
nil
pulmonari
oedema
cardiac
arrest
introduct
scorpion
antivenin
spider
antivenin
also
effect
safe
review
whole
igg
funnelweb
spider
antivenin
use
australia
report
complet
respons
recipi
one
local
reaction
one
case
anaphylaxi
one
case
serum
sick
whole
igg
black
widow
spider
lactodectru
antivenin
reduc
durat
symptom
hospitalis
moder
sever
envenom
us
review
intraven
compar
intramuscular
administr
associ
high
rate
anaphylaxi
eg
serum
sick
prior
reduc
speed
administr
reduc
total
advers
event
rate
less
equin
deriv
f
ab
black
widow
antivenin
develop
test
australian
studi
case
redback
spider
antivenin
f
ab
yield
case
anaphylaxi
serum
sick
rate
overal
polyclon
antibodi
use
antidot
also
reportedli
safe
studi
patient
receiv
antidigoxin
f
ab
reveal
allergi
rate
polyclon
serum
therapi
emerg
potenti
applic
rang
virus
limit
therapeut
option
highli
pathogen
avian
influenza
hpai
virus
new
target
polyclon
f
ab
immunoglobulin
therapi
stockpil
effect
product
prophylaxi
treatment
requir
anticip
epidem
neuraminidas
inhibitor
oseltamivir
remain
mainstay
treatment
overal
reduct
mortal
risk
report
report
oseltamivir
resist
hpai
well
season
human
influenza
strain
suggest
complementari
treatment
option
necessari
world
health
organis
recognis
potenti
role
serum
therapi
influenza
pandem
plan
given
histor
success
infecti
outbreak
use
convalesc
plasma
spanish
influenza
epidem
appar
reduc
mortal
convalesc
plasma
use
two
case
hpai
surviv
sinc
first
human
case
hpai
record
human
infect
death
januari
case
fatal
rate
case
africa
asia
middl
east
travel
return
survivor
produc
demonstr
neutralis
antibodi
whilst
current
limit
persontoperson
transmiss
antigen
shift
via
reassort
circul
human
virus
could
confer
set
stage
devast
pandem
vivo
proofofconcept
studi
equin
polyclon
f
ab
hpai
conduct
mice
product
abl
prevent
infect
intranas
hpai
challeng
seroneutralis
assay
haemagglutin
inhibit
test
confirm
potent
neutralis
abil
equin
polyclon
antihpai
f
ab
prepar
mice
anoth
studi
four
avian
influenza
equin
f
ab
prepar
demonstr
cytopath
effect
cultur
madindarbi
canin
kidney
mdck
cell
infect
protect
mice
lethal
challeng
given
prior
prophylaxi
post
therapeut
exposur
studi
concur
earlier
mice
studi
polyclon
antibodi
season
influenza
one
studi
mice
immunis
antigen
influenza
antiinfluenza
igg
obtain
intraven
inject
expos
mice
lead
surviv
high
dose
microgram
igg
phase
studi
healthi
young
human
male
age
year
receiv
intramuscular
polyclon
f
ab
hpai
yield
seriou
advers
event
chang
blood
urinari
paramet
one
febril
reaction
like
relat
product
also
evid
clinic
benefit
assess
seroneutralis
haemagglutin
inhibit
test
subject
plasma
sampl
ethic
placebocontrol
efficaci
studi
human
perform
effect
data
gather
compassion
casebas
use
fatal
avian
influenza
virus
emerg
peopl
march
avian
influenza
viru
emerg
china
spread
hong
kong
taiwan
malaysia
case
death
report
date
hpai
demonstr
rare
persontoperson
transmiss
may
first
case
avian
influenza
report
taiwan
three
human
case
avian
influenza
report
china
decemb
februari
low
pathogen
strain
current
potenti
remain
acquisit
mutat
may
increas
pathogen
sever
studi
suggest
potenti
role
respiratori
tract
administr
polyclon
prevent
treat
season
influenza
infect
suggest
potenti
appli
avian
influenza
strain
well
threat
new
avian
influenza
virus
middl
eastern
respiratori
syndrom
coronaviru
merscov
emerg
pandem
potenti
merscov
caus
sever
respiratori
ill
sometim
renal
injuri
whilst
case
occur
sever
middl
eastern
countri
particularli
saudi
arabia
case
report
korea
europ
north
africa
report
case
merscov
juli
die
larg
proport
case
may
go
undiagnos
appear
mix
zoonot
bat
andor
camel
human
sourc
transmiss
persontoperson
transmiss
particularli
document
healthcar
set
neither
specif
treatment
licenc
vaccin
recent
studi
serum
egyptian
dromedari
camel
seroposit
merscov
administ
mice
infect
merscov
australian
camel
seroneg
sera
serv
control
merscov
seroposit
camel
serum
given
preand
postexposur
protect
infect
mice
weight
loss
diminish
lung
histolog
chang
acceler
viru
clearanc
polyclon
antibodi
could
provid
postexposur
prophylaxi
close
contact
well
therapeut
strategi
sever
affect
merscov
one
potenti
set
develop
epidem
either
merscov
annual
hajj
pilgrimag
saudi
arabia
prepar
potenti
mer
outbreak
refin
equin
polyclon
antibodi
therapi
could
also
develop
widespread
sever
neglect
tropic
diseas
eg
viral
haemorrhag
fever
crimeancongo
haemorrhag
fever
dengu
ebola
marburg
battransmit
virus
nipah
hendra
well
lassa
viru
west
nile
viru
wnv
sever
acut
respiratori
syndromeassoci
coronaviru
sar
report
case
ebola
report
death
west
african
epidem
stockpil
polyclon
antibodi
may
form
part
epidem
prepar
anim
studi
exist
demonstr
efficaci
polyclon
antibodi
therapi
variou
neglect
tropic
viral
diseas
unimmunis
hamster
receiv
wnvimmun
hamster
antisera
one
hour
h
wnv
challeng
protect
lethal
wnv
infect
duck
egg
polyclon
f
ab
neutralis
and
viru
primari
agent
pulmonari
hantaviru
syndrom
south
america
vitro
hamster
given
polyclon
f
ab
postexposur
improv
surviv
compar
control
polyclon
antibodi
marburg
ebola
filovirus
acquir
nonhuman
primat
nhp
surviv
filoviru
challeng
given
postexposur
prevent
diseas
death
viruschalleng
nhp
compar
control
similar
result
obtain
inject
ebola
infect
mice
polyclon
sera
e
bola
immunis
mice
studi
mice
monkey
guinea
pig
demonstr
purifi
equin
whole
igg
prolong
surviv
ebola
equin
f
ab
verifi
protect
mice
hamster
develop
infect
sarscov
infect
given
prophylact
reduc
lung
viral
titr
given
therapeut
compar
control
summari
clinic
studi
demonstr
efficaci
animalderiv
polyclon
antibodi
therapi
variou
infect
toxin
venom
safeti
current
product
demonstr
clinic
trial
post
market
surveil
guidelin
follow
administ
rabi
equin
polyclon
antibodi
postexposur
prophylaxi
highli
effect
avert
rabi
antivenin
also
safe
effect
snake
arachnid
bite
avail
data
suggest
posit
effect
scorpion
bite
antidot
also
reportedli
safe
effect
polyclon
antibodi
develop
virus
epidem
pandem
potenti
prophylact
therapeut
option
current
limit
avian
influenza
zoonot
virus
preclin
studi
well
phase
safeti
studi
avian
influenza
promis
technolog
exist
rapidli
appli
method
polyclon
product
wide
rang
pathogen
antigen
provid
excit
opportun
revolutionis
prognosi
longstand
neglect
tropic
diseas
well
emerg
viral
threat
human
author
conflict
declar
